Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Mpox Vaccine

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age.